OPRM1 and neonatal abstinence syndrome: Camerota et al. showed that pharmacotherapy for NAS decreased DNA methylation in one of four CpG sites within the OPRM1 and was accompanied by improved clinical presentations, e.g., reduced irritability, signs of stress, and abnormal movements (81), suggesting the utility of biomarkers in monitoring disease progression in NAS.